Clinical Trials Browser

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT06084689 2025-09-02

EMPIRE

Tertiary Lymphoid Structures, Biliary Tract Neoplasms, Carcinoma, Non-Small-Cell Lung, Sarcoma, Colorectal Neoplasms, Triple Negative Breast Neoplasms

NCT03554109 2025-02-21

TNBC

Phase 2 Withdrawn

Breast

Triple Negative Breast Neoplasms

NCT05209529 2024-02-23

Chemo-free BRCA-targeted Neoadjuvant Strategy

Phase 2 Withdrawn

Breast

Triple Negative Breast Neoplasms

NCT05809895 2023-07-24

AdvanTIG-211

Phase 2 Withdrawn

Breast

Triple Negative Breast Neoplasms

NCT05255666 2023-07-11

Combination Liposomal Irinotecan and Pembrolizumab For Triple-Negative Breast Cancer (TNBC) With Brain Metastases (BM)

Phase 2 Withdrawn

BreastCNS

Brain Neoplasms, Triple Negative Breast Neoplasms

NCT03982173 2023-01-26

MATILDA

Phase 2 Withdrawn

BreastGastrointestinal

Adenocarcinoma Of Esophagus, Colorectal Neoplasms, Triple Negative Breast Neoplasms

NCT05008510 2022-02-08

VERU-111

Phase 2 Withdrawn

Breast

Triple Negative Breast Neoplasms

NCT02161679 2021-08-19

Phase II Study of IMMU-132 Alone or in Combination With Carboplatin in Patients With Triple-Negative Breast Cancer

Phase 2 Withdrawn

Breast

Triple Negative Breast Neoplasms

NCT04149444 2020-06-11

TACTIC

Phase 2 Withdrawn

Breast

Triple Negative Breast Neoplasms

NCT03644589 2019-04-26

Effect of Pembrolizumab and Cisplatin on Metastatic, Locally Recurrent or Inoperable Triple-Negative Breast Cancer

Phase 2 Withdrawn

Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT02685306 2017-03-09

A Study of Neoadjuvant Paclitaxel in Combination With Bavituximab in Early- Stage Triple- Negative Breast Cancer

Phase 2 Withdrawn

Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT02539017 2016-08-10

The Clinical Significance of Cellular Immune Adjuvant Therapy of Triple Negative Breast Cancer

Phase 2 Withdrawn

Breast

Triple Negative Breast Neoplasms

NCT01612910 2014-02-12

Oral Microencapsulated Diindolylmethane in Treating Patients With Stage II-III Triple Negative, Androgen Receptor Positive Breast Cancer Who Have Undergone Chemotherapy and Surgery

Phase 2 Withdrawn

Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

Clinical Trials

MK-5890-003

EMPIRE

TNBC

Chemo-free BRCA-targeted Neoadjuvant Strategy

AdvanTIG-211

Combination Liposomal Irinotecan and Pembrolizumab For Triple-Negative Breast Cancer (TNBC) With Brain Metastases (BM)

MATILDA

VERU-111

Phase II Study of IMMU-132 Alone or in Combination With Carboplatin in Patients With Triple-Negative Breast Cancer

TACTIC

Effect of Pembrolizumab and Cisplatin on Metastatic, Locally Recurrent or Inoperable Triple-Negative Breast Cancer

A Study of Neoadjuvant Paclitaxel in Combination With Bavituximab in Early- Stage Triple- Negative Breast Cancer

The Clinical Significance of Cellular Immune Adjuvant Therapy of Triple Negative Breast Cancer

Oral Microencapsulated Diindolylmethane in Treating Patients With Stage II-III Triple Negative, Androgen Receptor Positive Breast Cancer Who Have Undergone Chemotherapy and Surgery